MBio Diagnostics, Inc.
3122 Sterling Circle
About MBio Diagnostics, Inc.
MBio Diagnostics is enabling a new era in rapid, on-the-spot clinical diagnostics and sample testing. Our portable MBio Array System and disposable cartridges provide multiple quantitative answers in minutes.YEAR FOUNDED: 2009 LEADERSHIP: Founders: Christopher J. Myatt and Michael J. Lochhead Founder and CEO: Christopher J. Myatt Founder and CTO: Michael J. Lochhead
22 articles with MBio Diagnostics, Inc.
MBio Diagnostics and BARDA Partner on a 5-minute, Quantitative Point-of-Care COVID-19 Antibody Panel
MBio Diagnostics announced it has been awarded a $629,595 contract from the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop and commercialize their point-of-care multiplex serology test for the detection of human anti-SARS-CoV-2 antibodies.
MBio Diagnostics today announced delivery to the U.S. Department of Defense with funding for this effort provided by the Defense Health Program through the Joint Program Executive Office as part of a development program for a
MBio Diagnostics announced an expanded scope contract with the US Defense Advanced Research Projects Agency, where DARPA will apply additional resources and funds to accelerate progress towards FDA approval for MBio's LightDeck® platform.
MBio Diagnostics today announced two contracts with SRI International to develop tests related to homeland security on the MBio Diagnostics platform technology.
MBio Diagnostics, Inc., today announced two contracts to develop new tests for algae toxins. These tests will expand the offerings available on MBio's existing platform, the HAB Toxin System.
Sepsis tests will be developed in collaboration with the Cincinnati Children’s Hospital Medical Center (CCHMC) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) to address the critical need for more effective sepsis patient management in clinical and field settings
Funding Supports Scaling of Portable On-the-Spot Testing Platform
MBio Diagnostics, Inc. today announced a contract with the US Defense Advanced Research Projects Agency (DARPA) entitled, “Point-of-care Monitoring of the Host-Pathogen Interaction During Infection.”
MBio Diagnostics, Inc. today announced it has been awarded two additional patents for its LightDeck technology, a powerful fluorescence assay illumination and imaging approach.
MBio Diagnostics, Inc. and Foundation for Innovative New Diagnostics (FIND) Complete Phase I of TB Serology Program
MBio Diagnostics, Inc. Announces Sue Sutton-Jones Joins as VP of Regulatory Affairs and Quality Assuranc